| No. of patients (%) a |  | |
---|---|---|---|
Variable | Gefitinib | Erlotinib | P |
 | (n = 102) | (n = 95) |  |
Age (years) | |||
 Median [range] | 73 [37–90] | 68 [37–87] | 0.001 c |
 < 75 | 60 (59) | 78 (82) | < 0.001 d |
 ≥ 75 | 42 (41) | 17 (18) |  |
Sex | |||
 Male | 46 (45) | 50 (53) | 0.180 d |
 Female | 56 (55) | 45 (47) |  |
ECOG PS | |||
 0–1 | 86 (84) | 84 (88) | 0.417 d |
 2–3 | 16 (16) | 11 (12) |  |
Stage | |||
 I - III | 49 (48) | 36 (38) | 0.195 d |
 IV | 53 (52) | 59 (62) |  |
BSA (m2) | |||
 Median [range] | 1.5 [1.1–1.9] | 1.6 [1.1–2.0] | 0.045 c |
 <  1.6 | 70 (69) | 54 (57) | 0.105 d |
 ≥ 1.6 | 32 (31) | 41 (43) |  |
BMI (kg/m2) | |||
 Median [range] | 21.7 [14.9–31.3] | 22.0 [15.3–30.3] | 0.796 c |
 < BMI 25 | 83 (81) | 81 (85) | 0.568 d |
 ≥ BMI 25 | 19 (19) | 14 (15) |  |
Recurrence | |||
 Yes | 41 (40) | 34 (36) | 0.559 d |
 No | 61 (60) | 61 (64) |  |
Metastasis | |||
 Yes | 91 (89) | 88 (93) | 0.465 d |
 No | 11 (11) | 7 (7) |  |
Treatment line | |||
 First line | 59 (58) | 26 (27) | < 0.001 d |
 Second line and later line | 43 (42) | 69 (73) |  |
EGFR mutation | |||
 Exon 19 Deletion | |||
  Yes | 44 (43) | 34 (36) | 0.311 d |
  No | 58 (57) | 61 (64) |  |
 Exon 21 L858R point mutation | |||
  Yes | 51 (50) | 38 (40) | 0.197 d |
  No | 51 (50) | 57 (60) |  |
Smoking history | |||
 Yes | 39 (38) | 46 (48) | 0.154 d |
 No | 63 (62) | 49 (52) |  |
Grade 1 Liver dysfunction b | |||
 Yes | 37 (36) | 31 (33) | 0.654 d |
 No | 65 (64) | 64 (67) |  |